
    
      Phase 1 open-label study in stable schizophrenia patients designed to evaluate the safety,
      tolerability, and PK of switching from 2 mg/day or 3 mg/day oral risperidone to two DLP-114
      devices for a six or twelve-month dosing period.
    
  